General Oncology is dedicated to developing innovative treatments for metastatic cancer, particularly focusing on patients with inherited BRCA1, BRCA2, or PALB2 mutations. Their clinical pipeline includes a Phase 1 trial that combines melphalan, BCNU, vitamin B12b, and vitamin C, specifically targeting Stage IV cancers such as pancreatic and breast cancer. This treatment strategy aims to exploit the unique vulnerabilities of BRCA-mutated cancer cells to DNA crosslinking agents while addressing known mechanisms of drug resistance. The clinical trials are being conducted at prominent medical centers in Boston and New York, emphasizing the company's commitment to rigorous scientific evaluation.

In addition to their clinical efforts, General Oncology is advancing a preclinical pipeline aimed at a variety of solid tumors and hematological cancers, including myeloma, leukemia, and lymphoma. Their drug candidates are designed to selectively target and deactivate cancer cells while sparing healthy tissue, thereby enhancing treatment efficacy and minimizing side effects. The company is also exploring combinations of drugs to tackle multiple resistance mechanisms, with potential applications across a wide range of cancers, including gastric, lung, ovarian, melanoma, colorectal, brain, eye, bladder, and prostate cancers. This comprehensive approach underscores General Oncology's focus on leveraging established drugs to unlock new therapeutic potentials in the fight against cancer.

United States

Our pipeline of clinical and preclinical studies covers a range of solid tumors and blood cancers. We have an active clinical trial for metastatic cancers that arise in the setting of an inherited BRCA1, BRCA2, or PALB2 mutation.

General Oncology

Company Details